Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Rhea-AI Summary
Skye Bioscience (Nasdaq: SKYE) will present at the GLP-1-Based Therapeutics Summit in Boston, April 14–16, 2026.
The company’s presentation, titled "Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm," will be delivered by President & CEO Punit Dhillon on April 16 at 1:30 pm.
Positive
- None.
Negative
- None.
News Market Reaction – SKYE
On the day this news was published, SKYE declined 1.18%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: AVTX down 10.23%, FBRX up 2.48%, ZURA up 0.83%, while others are flat. This dispersion suggests SKYE’s modest 2.35% gain is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Dose expansion start | Positive | +5.0% | First patient treated in higher-dose Part C of CBeyond Phase 2a. |
| Mar 10 | Earnings and update | Positive | -9.7% | Reported 2025 results, nimacimab progress, and cash runway into Q4 2026. |
| Mar 05 | Earnings call date | Neutral | -0.3% | Announced timing and access details for 2025 results call. |
| Feb 02 | Phase 2a interim data | Positive | -7.9% | Reported 52-week CBeyond extension results with strong weight loss and safety. |
| Jan 29 | Preclinical obesity data | Positive | -5.0% | Presented nimacimab preclinical data showing enhanced weight loss with incretins. |
Recent history shows several positive nimacimab data updates followed by negative price reactions, indicating a pattern of selling into good clinical news.
Over the past few months, Skye has highlighted multiple milestones for nimacimab, including positive CBeyond Phase 2a data and initiation of a higher-dose expansion study. Despite constructive updates—such as 22.3% mean 52-week weight loss data and expansion plans to inform Phase 2b—shares often moved lower afterward. Against this backdrop, today’s conference presentation fits a pattern of ongoing visibility-building rather than a discrete value-inflecting catalyst.
Market Pulse Summary
This announcement highlights Skye’s participation in a GLP-1-focused summit, emphasizing its peripheral CB1 strategy in combination with GLP-1 agonists for obesity. It follows recent clinical progress and proxy disclosures on higher-dose expansion and long-term weight loss data. Investors may track how conference visibility supports partnering or trial enrollment, while monitoring upcoming Phase 2b planning milestones and future data updates to gauge the program’s evolution.
Key Terms
glp-1 agonists medical
cb1 antagonism medical
AI-generated analysis. Not financial advice.
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in Boston, MA, being held April 14-16.
Presentation Details
Title: Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm
Presenter: Punit Dhillon, President & CEO
Date: Thursday, April 16, 2026
Time: 1:30 pm
About Nimacimab
Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous system penetration, potentially limiting neuropsychiatric side effects seen with small-molecule antagonists. As a non-incretin, non-peptide agent, nimacimab acts independently of the GLP-1 pathway and has demonstrated additive effects in combination with semaglutide in the Phase 2a CBeyond trial. The Company is developing nimacimab as a potential orthogonal add-on therapy for patients with obesity who are experienced on or have plateaued with GLP-1-based treatment, targeting clinically meaningful incremental weight loss, improved body composition, and reduced weight regain without added gastrointestinal or neuropsychiatric burden.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity and overweight for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(415) 269-7757
FORWARD-LOOKING STATEMENTS
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements relating to: the potential for higher dosing of nimacimab to achieve increased efficacy; the potential for the combination of nimacimab and semaglutide to deepen weight loss and mitigate weight rebound; the potential for future weight loss beyond 52 weeks; plans to advance nimacimab into the next stage of development to optimize dosing; future clinical development of nimacimab, including the initiation and design of any future clinical trials; the expected timing for reporting topline data from the Phase 2a extension study; the ability of nimacimab to drive weight loss without neuropsychiatric and other adverse events; the potential for nimacimab to be a first-in-class drug; the potential for Skye to develop a leading orthogonal platform to intensify incretin outcomes and help patients achieve more durable metabolic benefit; the commercially competitive nature of nimacimab combined with semaglutide; and the potential for nimacimab to be a long term option in obesity and related metabolic diseases. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “planning,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon Skye’s current expectations and various assumptions. Skye believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Skye may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important risks and uncertainties, including, without limitation, the initiation and design of any future clinical trials will be impacted by Skye’s capital resources, Skye’s ability to obtain additional sources of capital needed to run an additional Phase 2 clinical trial, program considerations and potentially other factors outside the Skye’s control; the potential for additional weight loss after 52 weeks may not ultimately be observed; there is no guarantee that higher dosing of nimacimab will achieve increased efficacy, and likewise it is possible that higher dosing will produce adversely different safety and tolerability results than those observed to date; Skye’s dependence on third parties in connection with product manufacturing; research and preclinical and clinical testing; Skye’s ability to advance, obtain regulatory approval of and ultimately commercialize nimacimab, competitive products or approaches limiting the commercial value of nimacimab; the timing and results of preclinical and clinical trials; Skye’s ability to fund development activities and achieve development goals; the impact of any global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, adverse regulatory changes; Skye’s ability to protect its intellectual property; risks associated with Skye’s common stock and the other important factors discussed under the caption “Risk Factors” in Skye’s filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024, which are accessible on the SEC’s website at www.sec.gov and the Investors section of Skye’s website. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Skye may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause Skye’s views to change. These forward-looking statements should not be relied upon as representing Skye’s views as of any date subsequent to the date of this press release.
